Market timing · 2026

Почему сейчас

Reasonable вопрос любому solo-founder biotech в 2026: почему это credibly possible сейчас, когда было delusional пять лет назад? Честный ответ имеет четыре части.

1. AAV manufacturing economics inverted

Per-dose AAV cost для preclinical research-grade material fell by roughly an order of magnitude since 2019, driven by suspension-cell platforms, transient transfection optimization и competition среди CDMOs (PackGene, Vigene, Vector BioMed, Charles River, Aldevron). Academic vector cores routinely produce small-batch AAV9 для preclinical studies в low five figures. Solo founder bootstrapping в 2020 could credibly contemplate in vivo work без institution. В 2026 in vivo line item для 3-model syngeneic study at single CRO partner sits в high six до low seven figures — comfortably inside normal pre-seed round.

2. Structural prediction at therapeutic-design quality

AlphaFold2 (2021) made backbone prediction reliable. AlphaFold3 и RoseTTAFold all-atom (2024–2025) extended это к ligand и complex prediction. ESM и inverse-folding models (ESM-IF, ProteinMPNN) закрыли loop по de novo sequence generation. End-to-end design chimeric receptor-effector fusion, который previously required structural biology lab и 18 месяцев, теперь может iterated computationally в недели.

3. Solo-founder operating leverage from production agent stacks

Работа, которая genuinely benefits from AI augmentation — это operational dark matter — freedom-to-operate scanning across 80M patent documents, competitive intelligence updates from 200+ company pipelines, regulatory document drafting, codon-optimization scripting, internal IP-strategy diary. Три года назад каждое из этого required dedicated headcount. Production agent stack на Vercel Edge с Anthropic SDK, deterministic prompt-routing и hardened input layer (NFKC normalization + 22-pattern injection scanner) handles operational floor 6-person team at marginal cost API calls. Это actual delta. Nightbox — one founder, built на top of этого delta.

4. Peto's-paradox окно открыто

Elephant LIF6 work (Vazquez 2018, Cell Reports) и broader literature по duplicated TP53 и re-functionalized pseudogenes в elephant cancer resistance been public в течение почти decade. NKG2D-CAR therapies имеют IND clearance и Phase 1 data (Fate Therapeutics FT536, Celyad CYAD-101). Никто fused two — chimeric receptor-effector с NKG2D's tumor selectivity, layered onto LIF6's mitochondrial kill mechanism. IP whitespace genuinely clean. Whitespaces в oncology gene therapy stay open forever.

Что это значит

Ничего из вышеперечисленного eliminates need для in vivo validation. Ничего из этого eliminates need для wet-lab scientific lead, ex-FDA regulatory voice и tumor immunology PI на SAB. Ничего из этого eliminates need для IND-enabling toxicology. Вышеперечисленное — почему программа tractable для small team в 2026. Это substitute для programme.

Литература

• Vazquez et al. (2018). LIF6 retrogene reactivation in elephants. Cell Reports.
• Sulkowski et al. AAV manufacturing cost-curve analyses, ASGCT proceedings 2023–2025.
• Jumper et al. (2021). AlphaFold2. Nature.
• Abramson et al. (2024). AlphaFold3. Nature.
• Krienke et al. NKG2D-CAR clinical landscape reviews 2023–2025.